AZD-4041
- Generic Name
- AZD-4041
Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).
Phase 1
Terminated
- Conditions
- Opioid Use Disorder
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT06406400
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT05587998
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
A Safety Study of AZD4041 in Healthy Participants
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT05233085
- Locations
- 🇨🇦
Research Site, Laval, Quebec, Canada
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT04076540
- Locations
- 🇺🇸
Research Site, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath